A probable diagnosis of von HippelLindau disease was made in a two generation family in which the proband had a phaeochromocytoma, renal cysts, and multiple cerebral cavernomas. His sister had multiple similar cerebral vascular lesions and his father died from renal carcinoma aged 42. Although the family did not satisfy the conventional diagnostic criteria for von Hippel-Lindau disease, an underlying germline mutation in the von Hippel-Lindau disease tumour suppressor gene was identified in the proband. Molecular genetic analysis not only confirmed the putative diagnosis of the disease in the proband but also showed that the cerebral vascular lesions segregated independently from the von HippelLindau disease mutation. This report exemplifies how molecular genetic investigations can enhance the diagnosis and management of families with suspected von Hippel-Lindau disease, particularly when the manifestations, as in this family, are not typical.
Von Hippel-Lindau (VHL) disease is a dominantly inherited familial cancer syndrome with an estimated birth incidence of heterozygotes of about 1 in 36 000.
1 2 The main manifestations include benign vascular tumours (haemangioblastomata) of the retina, cerebellum, and spinal cord, renal carcinoma, phaeochromocytoma, and renal and pancreatic cysts. Retinal and CNS tumours are the most frequent manifestations occurring in 70% and 84% of gene carriers respectively by the age of 60.
2 Supretentorial tumours are rare in VHL disease but have been reported. 3 4 The diagnosis of the disease is dependent on finding (1) two haemangioblastomas, (2) a haemangioblastoma and a visceral complication, or (3) one manifestation if there is a family history of haemangioblastoma. To identify gene carriers within VHL pedigrees and to detect retinal, adrenal, and renal tumours at a presymptomatic stage when treatment is most eVective, a screening protocol has been recommended. 3 Although the disease penetrance is close to 100% by the age of 60 years, the variability in expression can often complicate accurate clinical diagnosis.
The disease was found to be linked to markers on chromosome 3p 5 and the gene was later characterised by a positional cloning approach. 6 Mutations have been identified in most VHL kindred 7 8 and include deletions of the whole gene, deletion of one or two of the three exons, or intragenic point mutations including missense, nonsense, microdeletions, or insertions. A phenotype-genotype relation is evident in that missense mutations are associated with a high risk of phaeochromocytoma and mutations predicted to cause an absent or truncated protein produce a low risk of this complication. Recent advances in the understanding of the molecular genetics of VHL disease allow presymptomatic diagnosis of at risk relatives by linkage analysis using informative markers close to the VHL gene 9 or by mutational analysis when the family mutation has been determined.
In addition to the classic features of the disease, many rare complications have been reported. In some cases it is not clear whether these are chance associations or true rare manifestations. We report a family in which a clinical diagnosis of probable VHL disease was made and in which multiple cerebral cavernomas occurring in two siblings seemed to be a rare manifestation. Molecular genetic analysis confirmed a diagnosis of VHL disease in one family member but also showed that the cerebral vascular lesions were not manifestations of the disease. Figure 1 shows the family pedigree.
Patients and methods

CLINICAL DETAILS
Patient III:2 presented at the age of 22 with blurred vision and headaches. Examination disclosed hypertension and grade IV hypertensive retinopathy and subsequent investigation showed left adrenal and periaortic phaeochromocytomas. These were successfully resected with relief of hypertension and sympathetic symptoms. At the age of 31 he had two epileptic seizures. Brain MRI showed multiple cerebral cavernomas (fig 2A) . A diagnosis of VHL disease was made on the basis of these findings. Further screening disclosed multiple renal cysts but no evidence of retinal angiomata or recurrence of phaeochromocytoma. He has no children. Blood DNA was analysed for VHL markers and mutation screening.
Patient III:3 developed epilepsy at the age of 25 which has subsequently been successfully controlled on medication. Brain MRI showed cerebral vascular lesions similar to those of her brother (III:2) ( fig 2B) . There were no abnormalities in the cerebellum, brainstem, or spinal cord. Retinal examination showed no evidence of angiomata. Abdominal imaging was normal. She had borderline hypertension that did not require treatment and urinary VMAs were within normal limits. She has no children.
Blood DNA was analysed for VHL markers and mutation screening.
Other family members
Member II:1, the father of III:2 and III:3, died aged 42 from renal carcinoma. He had no other manifestations of VHL disease that were known to his relatives; II:2, the mother of III:2 and III:3, is aged 55 and fit and well with no manifestations of the disease. Member III:4 is the dizygotic twin of III:3. She is mentally handicapped and has no evident manifestations of VHL disease. Member III:1 is the eldest sister of III:2 and III:3 and is aged 37. These remaining members of the family were either unavailable for interview or declined to donate a blood sample for DNA analysis.
Molecular genetic analysis
Blood was available from patients III:2 and III:3 and DNA was extracted using standard methods. The patients were typed for the highly informative microsatellite polymorphism D3S1038 as described previously 9 and were found to share one allele. To detect the specific VHL mutation, Southern blot analysis was first performed on blood DNA from III:2 to detect or exclude a large deletion in the VHL gene. Five micrograms of genomic DNA was digested with 1U of EcoRI (Boehringer Mannheim) at 37°C as recommended by the manufacturers and then run overnight on a 0.8% agarose gel. The DNA was transferred to a Hybond nitrocellulose filter using standard methods and probed with VHL cDNA (g7) as described previously. 10 A single band of 22 kb was detected after autoradiography from patient III:2 with no other bands evident suggesting the absence of a large VHL gene deletion.
The polymerase chain reaction (PCR) was used to amplify the VHL coding region in four fragments and single strand conformation polymorphism analysis was performed to detect intragenic mutations as described previously. 7 Analysis of exon 3 showed a bandshift not seen in DNA from normal subjects. The exon 3 PCR fragment was purified using a Promega Wizard TM purification column and the fragment sequenced on the ABI TM 373 automated sequencer using dye terminator chemistry (amplitaq FS) as recommended by the manufacturers.
Sequencing disclosed a C to T transition at nucleotide 796 in DNA from patient III:2 causing a nonsense mutation (glutamine to stop) at codon 195 (fig 3 left) . This would be predicted to cause a truncated protein product deleted for the 19 carboxy terminal amino acids of the 213 amino acid VHL protein. Similar analysis of blood DNA from patient III:3, who was assumed to be aVected by VHL disease, showed a normal SSCP pattern for exon 3 and a normal exon 3 sequence (fig 3 right) .
Discussion
Symptoms and signs of CNS haemangioblastomata are common presentations of VHL disease and awareness of this rare familial disease is important to neurologists and neurosurgeons. Symptomatic cerebellar haemangioblastomata occur in about 59% of patients with the disease 3 and cause neurological deficit through local pressure eVects and cyst formation from exuded fluid. They can also haemorrhage. Spinal and brainstem lesions are less common than cerebellar lesions but cause neurological symptoms in about 13% of patients. 3 The actual prevalence of CNS haemangioblastomata is much higher if asymptomatic lesions are included after MRI screening.
11 Supratentorial lesions are rare in VHL disease but have been reported 3 4 and the reason for this specific distribution of CNS tumours in the disease is unknown. Haemangiomata appear as homogeneous enhancing nodules often associated with a cyst on neuroradiological imaging.
Cavernomas of the CNS are also rare with an estimated prevalence of 0.5%. 12 They present with seizures, headaches, and focal neurological deficit or they can remain asymptomatic. On MRI, there are often multiple lesions that show a heterogeneous appearance. Typically, on T2 weighted images both low intensity areas (due to haemosiderin) and high intensity areas (due to other haemoglobin breakdown products) are seen, as was the case with our patients (fig 2) . Cavernomas are thought to be familial in at least 50% of cases (more when multiple lesions are present) when they show autosomal dominant inheritance. Recently a locus has been mapped to chromosome 7q in one large family. 13 The diagnosis of gene carriers in VHL pedigrees is important as it allows accurate genetic counselling and appropriate screening for presymptomatic detection of treatable manifestations. The variability of VHL disease can obfuscate the diagnosis. The utility of molecular genetic testing in the clarification of diagnosis in such situations is exemplified by this report, which illustrates the danger of overinclusiveness. Without such tests, the genetic counselling oVered to this family, particularly patient III:3, would have been inappropriate. Other manifestations that can lead to diagnostic confusion include renal cysts, unusual retinal lesions not typical of angiomata, and other rare lesions such as liver cysts and liver haemangiomata. 4 14 Susceptibility to phaeochromocytoma is low in families with mutations in which the VHL protein is deleted or truncated. 15 The explanation for this phenotype-genotype relation, which was not confirmed in our patient (III:2) is uncertain but may indicate tissue specific functions of the VHL protein. One other phaeochromocytoma positive VHL family has been shown to have a nonsense mutation at the same codon as the family reported here. 7 This suggests that the carboxy terminal 19 amino acids are necessary for normal tumour suppressor function. 
